BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
BioAge Labs, Inc. First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data...
BioAge
BioAge Labs, Inc. First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data...
